RDHL PE Ratio & Valuation,Is RDHL Overvalued

RDHL Relative Valuation

RDHL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RDHL is overvalued; if below, it's undervalued.

Historical Valuation

Redhill Biopharma Ltd (RDHL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.11 is considered Undervalued compared with the five-year average of -7.22. The fair price of Redhill Biopharma Ltd (RDHL) is between 37.90 to 57.50 according to relative valuation methord. Compared to the current price of 1.20 USD , Redhill Biopharma Ltd is Undervalued By 96.83%.

Relative Value

Fair Zone

37.90-57.50

Current Price：1.20

96.83%

Undervalued

0.02

0.00

EV/EBITDA

Redhill Biopharma Ltd. (RDHL) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.93. The thresholds are as follows: Strongly Undervalued below -9.88, Undervalued between -9.88 and -5.90, Fairly Valued between 2.05 and -5.90, Overvalued between 2.05 and 6.02, and Strongly Overvalued above 6.02. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.21

EV/EBIT

Redhill Biopharma Ltd. (RDHL) has a current EV/EBIT of -0.21. The 5-year average EV/EBIT is -3.51. The thresholds are as follows: Strongly Undervalued below -12.70, Undervalued between -12.70 and -8.11, Fairly Valued between 1.08 and -8.11, Overvalued between 1.08 and 5.67, and Strongly Overvalued above 5.67. The current Forward EV/EBIT of -0.21 falls within the Historic Trend Line -Fairly Valued range.

0.11

Redhill Biopharma Ltd. (RDHL) has a current PS of 0.11. The 5-year average PS is 1.21. The thresholds are as follows: Strongly Undervalued below -0.94, Undervalued between -0.94 and 0.14, Fairly Valued between 2.29 and 0.14, Overvalued between 2.29 and 3.37, and Strongly Overvalued above 3.37. The current Forward PS of 0.11 falls within the Undervalued range.

-2.11

P/OCF

Redhill Biopharma Ltd. (RDHL) has a current P/OCF of -2.11. The 5-year average P/OCF is -4.37. The thresholds are as follows: Strongly Undervalued below -21.95, Undervalued between -21.95 and -13.16, Fairly Valued between 4.41 and -13.16, Overvalued between 4.41 and 13.20, and Strongly Overvalued above 13.20. The current Forward P/OCF of -2.11 falls within the Historic Trend Line -Fairly Valued range.

-0.45

P/FCF

Redhill Biopharma Ltd. (RDHL) has a current P/FCF of -0.45. The 5-year average P/FCF is -1.13. The thresholds are as follows: Strongly Undervalued below -4.26, Undervalued between -4.26 and -2.69, Fairly Valued between 0.43 and -2.69, Overvalued between 0.43 and 2.00, and Strongly Overvalued above 2.00. The current Forward P/FCF of -0.45 falls within the Historic Trend Line -Fairly Valued range.

Redhill Biopharma Ltd (RDHL) has a current Price-to-Book (P/B) ratio of -0.49. Compared to its 3-year average P/B ratio of 55.70 , the current P/B ratio is approximately -100.88% higher. Relative to its 5-year average P/B ratio of 35.27, the current P/B ratio is about -101.40% higher. Redhill Biopharma Ltd (RDHL) has a Forward Free Cash Flow (FCF) yield of approximately -204.64%. Compared to its 3-year average FCF yield of -302.23%, the current FCF yield is approximately -32.29% lower. Relative to its 5-year average FCF yield of -203.64% , the current FCF yield is about 0.49% lower.

-0.49

P/B

Median3y

55.70

Median5y

35.27

-204.64

FCF Yield

Median3y

-302.23

Median5y

-203.64

Competitors Valuation Multiple

The average P/S ratio for RDHL's competitors is 0.00, providing a benchmark for relative valuation. Redhill Biopharma Ltd Corp (RDHL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -90.21%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of RDHL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of RDHL in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Redhill Biopharma Ltd (RDHL) currently overvalued or undervalued?

What is Redhill Biopharma Ltd (RDHL) fair value?

RDHL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Redhill Biopharma Ltd (RDHL) is between 37.90 to 57.50 according to relative valuation methord.

How does RDHL's valuation metrics compare to the industry average?

What is the current P/B ratio for Redhill Biopharma Ltd (RDHL) as of Dec 16 2025?

As of Dec 16 2025, Redhill Biopharma Ltd (RDHL) has a P/B ratio of -0.49. This indicates that the market values RDHL at -0.49 times its book value.

What is the current FCF Yield for Redhill Biopharma Ltd (RDHL) as of Dec 16 2025?

As of Dec 16 2025, Redhill Biopharma Ltd (RDHL) has a FCF Yield of -204.64%. This means that for every dollar of Redhill Biopharma Ltd’s market capitalization, the company generates -204.64 cents in free cash flow.

What is the current Forward P/E ratio for Redhill Biopharma Ltd (RDHL) as of Dec 16 2025?

As of Dec 16 2025, Redhill Biopharma Ltd (RDHL) has a Forward P/E ratio of 0.02. This means the market is willing to pay $0.02 for every dollar of Redhill Biopharma Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Redhill Biopharma Ltd (RDHL) as of Dec 16 2025?

As of Dec 16 2025, Redhill Biopharma Ltd (RDHL) has a Forward P/S ratio of 0.11. This means the market is valuing RDHL at $0.11 for every dollar of expected revenue over the next 12 months.

RDHL Valuation